X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

OKYO

Closed

Okyo Pharma Ltd Adr

2.61
+0.04 (+1.56%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.57
Day's Range: 2.47 - 2.66
Send
When Written:
 
1.29
OKYO Pharma Ltd is a biopharmaceutical company that focuses on the discovery and development of novel drugs to treat inflammatory diseases and cancer. The company's lead drug candidate, OK-432, is a potential treatment for cancer and is currently in clinical trials. OKYO Pharma Ltd is headquartered in London, UK, and its American Depository Receipts (ADRs) trade on the OTCQB market under the ticker symbol OKYPY. As of August 2021, the company's ADRs were trading at around $3.50 per share.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
When Written:
 
1.29
OKYO Pharma Ltd is a clinical-stage biotechnology company that focuses on the development of innovative drugs to address unmet medical needs. The company's lead product candidate, OK-101, is a potential treatment for dry eye disease, which is currently in Phase II clinical trials. OKYO Pharma is also developing a pipeline of other drug candidates for various indications, including cancer, autoimmune diseases, and viral infections. The company is headquartered in London, UK, and trades on the NASDAQ exchange under the ticker symbol OKYO.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.11
X